Is Cancer a Metabolic Disease? Seyfried's Theory, Keto Protocol & Repurposed Drugs (2026)

Quick Answer The Somatic Mutation Theory (SMT) — the model that has guided oncology since the 1970s — holds that cancer starts with random DNA mutations. The 2005 Cancer Genome Atlas Project largely dismantled that idea: no "founding mutation" was ever found, and mutation patterns varied wildly between and within tumors. The Metabolic Theory of Cancer (MTOC), developed by Dr. Thomas Seyfried at Boston College from decades of mitochondrial research (Otto Warburg, Peter Pedersen), argues that cancer originates from damaged mitochondria forcing cells into fermentation-based energy production (the Warburg effect), with nuclear mutations arising downstream as a consequence, not a cause. This reframing supports combining standard oncology with ketogenic/calorie-restricted metabolic protocols, repurposed drug combinations (e.g., metformin, statins, mebendazole, doxycycline), and cancer-stem-cell-targeting agents — approaches now backed by published trials such as CUSP9, METRICS, CLOVA, and COMBAT. The evidence remains mixed and evolving; this is not a replacement for standard oncology care.

Medically reviewed by the OneDayMD Editorial Team | Last updated: July 2026

Table of Contents

1. The Theory That May Have Cost Millions of Lives 2. Two Theories of Cancer: A Fundamental Disagreement 3. The Cancer Genome Atlas and the Collapse of the Somatic Mutation Theory 4. Warburg, Pedersen, and the Nuclear Transfer Experiments 5. The Warburg Effect and the Ketogenic "Press-Pulse" Protocol 6. Glutamine: The Fuel Warburg Missed 7. Published Case Reports on Metabolic Cancer Therapy 8. Repurposed Drug Trials: CUSP9, METRICS, CLOVA, COMBAT 9. Cancer Stem Cells: The Target Standard Therapy Misses 10. A Balanced Look: What the Skeptics and Reviews Say 11. Integrative Oncologists Using Metabolic Protocols 12. A Practical Prevention & Support Framework 13. Frequently Asked Questions 14. References

1. The Theory That May Have Cost Millions of Lives

In 1971, President Nixon declared a "War on Cancer." Hundreds of billions of dollars in research funding later, the results have been, by most honest accountings, disappointing. Cancer deaths have risen 9% since 1950. The overall contribution of chemotherapy to five-year survival in adults has been estimated at roughly 2% in the United States and 2.3% in Australia. Over the past fifteen years, new cancer therapies have improved average overall survival by around 2.4 months; over the past thirty years, the cumulative gain from experimental treatment has been roughly 3.4 months.

A 2025 BMC Cancer study found that 30-day mortality after systemic anti-cancer therapy (chemotherapy) was approximately 7%, rising to an estimated 15–18% when chemotherapy was combined with immunotherapy — meaning a meaningful share of patients died within a month of their final treatment dose.

These numbers describe a field that many researchers now argue has been looking in the wrong place — the cell nucleus — for seventy years, guided by a framework called the Somatic Mutation Theory. Evidence undermining that framework has existed in the scientific literature for over a decade. This article merges the mechanistic case laid out by Dr. Pierre Kory's Leading Edge Clinic with OneDayMD's ongoing coverage of Dr. Thomas Seyfried's metabolic model, the clinical protocols built around it, and — importantly — the published critiques and limitations that any responsible review of this space has to include.

2. Two Theories of Cancer: A Fundamental Disagreement

The Somatic Mutation Theory (SMT) holds that cancer arises from an accumulation of genetic mutations in nuclear DNA. Carcinogens damage tumor suppressor and tumor promoter genes, driving cells toward the eight "hallmarks of cancer" described by Hanahan and Weinberg (2011): uncontrolled growth, evasion of cell death, immune evasion, invasiveness, and altered energy metabolism. SMT has underpinned the entire field of targeted therapy — drugs designed to counteract the downstream products of specific mutations.

The Metabolic Theory of Cancer (MTOC) proposes the opposite causal sequence. Cancer begins with damage to the mitochondria — the cell's energy-producing organelles — which lose the ability to use oxygen efficiently and are forced into glucose fermentation (the "Warburg effect," first described by Nobel laureate Otto Warburg in 1927). This metabolic breakdown sends distress signals back to the nucleus (the "retrograde response"), disrupting DNA repair and activating oncogenes. Under MTOC, nuclear mutations are a consequence of mitochondrial dysfunction, not its origin.

Feature	Somatic Mutation Theory (SMT)	Metabolic Theory of Cancer (MTOC)
Origin site	Cell nucleus (DNA)	Mitochondria (cytoplasm)
Primary driver	Carcinogen-induced gene mutations	Damaged mitochondrial energy metabolism
Role of mutations	Cause of cancer	Downstream effect of mitochondrial stress
Treatment logic	Target specific mutations (targeted therapy)	Restrict fermentable fuels; target metabolic pathways
Key evidence	TCGA found no consistent "founding mutation"	Nuclear transfer experiments; Warburg effect; PET scan biology

3. The Cancer Genome Atlas and the Collapse of the Somatic Mutation Theory

In 2005, the Cancer Genome Atlas Project (TCGA) set out to sequence cancer genomes across multiple tumor types to identify the mutations presumed to drive them. Bert Vogelstein — the researcher who had shown p53 mutations occur in more than half of cancers — was central to the effort.

What TCGA found instead undercut the theory it was designed to confirm: mutations appeared essentially at random across the genome rather than in an orderly progression; few new oncogenes emerged; mutations varied dramatically between patients with the same cancer type and even between cells within a single tumor; and in breast cancer, some tumors were found with no mutations at all despite behaving aggressively. No single "founding mutation" — one that should be present in every cell of a tumor if SMT were correct — has ever been identified.

In response, Vogelstein progressively modified the theory, eventually proposing twelve distinct biological systems cancer might disrupt — a move Travis Christofferson's book Tripping Over the Truth described as an ad hoc adjustment to fit a failing model to contradictory data. Meanwhile, roughly 700 targeted-therapy agents tested in solid-tumor patients over the past decade have produced zero drugs that extended survival by a full year compared with conventional treatment.

4. Warburg, Pedersen, and the Nuclear Transfer Experiments

Otto Warburg discovered in 1927 that cancer cells rely almost exclusively on glucose fermentation for energy even when oxygen is available — a finding so significant it won him the 1931 Nobel Prize. This "Warburg effect" is, notably, the biological basis of the PET scan: oncologists inject radio-labeled glucose (FDG) and identify tumors by their abnormally high glucose uptake. Every clinician who orders a PET scan is implicitly relying on the Warburg effect — while many simultaneously tell patients that diet has no bearing on their cancer.

Warburg could never fully explain why cancer cells behave this way. That answer began taking shape through the work of biochemist Peter Pedersen starting in 1979, who documented that cancer cells have structurally abnormal mitochondria — fewer in number, smaller, with defective membranes — and an overactive form of hexokinase that simultaneously drives glucose consumption and blocks apoptosis.

Dr. Thomas Seyfried, Professor of Biology at Boston College, synthesized these findings into a complete theory, anchored by nuclear transfer experiments from the 1980s. When researchers transplanted a cancer cell's nucleus into a healthy cell (with its own nucleus removed), the resulting cell largely did not behave cancerously — the healthy mitochondria appeared to suppress the cancerous nuclear DNA. The reverse experiment was more striking: transferring mitochondria from a cancer cell into a normal cell with a healthy nucleus caused cancer to develop in roughly 97% of the resulting mice. Seyfried published this synthesis in his 2012 book Cancer as a Metabolic Disease.

To be precise, MTOC does not claim nuclear mutations don't exist in cancer — they clearly do. It argues they are consequences of mitochondrial dysfunction (via the "retrograde response") rather than the initiating cause, which is why Seyfried and others describe SMT as incomplete rather than entirely wrong. The two frameworks are increasingly discussed as complementary rather than mutually exclusive; most clinicians working in this space, including those cited in this article, do not recommend forgoing standard oncology care.

5. The Warburg Effect and the Ketogenic "Press-Pulse" Protocol

The most direct clinical implication of MTOC is dietary. If cancer cells depend on glucose fermentation, and healthy cells can switch to burning ketone bodies from fat when glucose is scarce (a metabolic flexibility damaged mitochondria generally lack), then a ketogenic or calorie-restricted diet may create an environment that disadvantages cancer cells while sustaining normal ones.

In animal models, Seyfried found ketogenic and calorie-restricted diets to be anti-angiogenic, pro-apoptotic, and anti-invasive. Human studies (observational and small trials) suggest potential benefit across breast, brain, colon, pancreatic, lung, and prostate cancers, along with reduced chemotherapy side effects when combined with standard treatment. Seyfried's own framing is blunt: "No tumor cell can survive in the absence of both glucose and glutamine, especially when ketones are used to support the viability of normal cells."

Seyfried and colleagues formalized this into the "press-pulse" protocol: a sustained metabolic "press" (ketogenic diet plus glutaminase-inhibiting strategies plus stress management) intended to weaken cancer cells systemically, paired with an intermittent "pulse" — which may be a non-toxic intervention like hyperbaric oxygen or IV vitamin C, or a conventional modality like chemotherapy or radiation — aimed at cells already metabolically stressed by the press phase. Patient community feedback on this protocol (including clinicians and caregivers who have implemented it) generally emphasizes that the ketogenic "press" is intended as a defined-duration therapeutic tool during active treatment, not necessarily a lifelong diet, and that it should be monitored via blood glucose and ketone tracking rather than adopted casually.

Normal Cell vs. Cancer Cell Metabolism
Normal cell: functional mitochondria → oxidative phosphorylation → ~36–38 ATP per glucose molecule → CO₂ and water as byproducts → dim on PET scan	Cancer cell: damaged mitochondria → aerobic glycolysis (fermentation, even with oxygen present) → ~2 ATP per glucose molecule → lactate as byproduct → bright on PET scan

6. Glutamine: The Fuel Warburg Missed

Seyfried's research adds a second fermentable fuel that Warburg didn't isolate: the amino acid glutamine. As Seyfried has put it, cancer cells "cannot breathe... they can only get energy from fermentation," surviving without oxygen but not without glucose and glutamine. This is why press-pulse protocols pair carbohydrate restriction with strategies to inhibit glutaminolysis.

Among natural compounds studied for this purpose, EGCG (epigallocatechin gallate) from green tea has some of the more established data, acting on glutamate dehydrogenase (GDH), the enzyme that converts glutamate into alpha-ketoglutarate during glutaminolysis. Berberine has also been proposed as promising for glutamine-driven tumors, pending resolution of bioavailability/delivery challenges. These remain adjunctive, evidence-graded considerations — not substitutes for prescribed glutaminase-inhibitor drug therapy, which requires medical supervision.

7. Published Case Reports on Metabolic Cancer Therapy

A number of individual case reports in the peer-reviewed literature describe favorable outcomes when metabolic interventions were combined with other treatments. These are illustrative, not representative — case reports are the weakest form of clinical evidence and are typically published because the outcome was unusual.

• Stage IV breast cancer (Cureus, 2021): A 47-year-old woman with metastatic breast cancer to brain, lungs, liver, and bone received metabolically supported chemotherapy, a ketogenic diet, hyperthermia, and hyperbaric oxygen at a clinic in Istanbul. All detectable lesions resolved after six months, with the response sustained at two years on maintenance therapy.
• Glioblastoma (Frontiers in Nutrition, 2018): A 38-year-old man's tumor shrank roughly 1.5 cm in diameter after 20 months of ketogenic diet therapy alongside chemotherapy and radiotherapy.
• Stage IV triple-negative breast cancer (Cureus, 2017): A 29-year-old woman achieved a complete pathological response after six months combining metabolically supported chemotherapy, ketogenic diet, hyperthermia, and hyperbaric oxygen.
• Metastatic lung cancer (Cureus, 2022): A 54-year-old man whose brain and lung tumors did not respond to chemotherapy or radiation saw shrinkage after adopting a ketogenic diet, with stable disease at nine years of follow-up.
• Stage IV breast cancer via press-pulse therapy: A 45-year-old Ohio woman given less than a month to live in 2018 began press-pulse therapy; by her last documented check-up in March 2021, her disease was stable with no recurrence.

A related randomized trial (Clinical Nutrition, 2021) of 80 women with locally advanced/metastatic breast cancer found lower serum insulin and reduced tumor size in the ketogenic diet arm over 12 weeks compared to controls.

8. Repurposed Drug Trials: CUSP9, METRICS, CLOVA, COMBAT

Metabolic vulnerabilities in cancer cells can potentially be targeted by drugs already approved for other indications — the foundation of the "repurposed drug" approach. Dr. Paul Marik, co-founder of the FLCCC, reviewed nearly 1,500 references on repurposed drugs and nutraceuticals in his book Cancer Care, grading 17 compounds as having strong evidence, 8 as weak, and 15 as insufficient. The trials below, conducted primarily outside the U.S., report meaningful survival differences versus historical controls — though none are large, blinded, randomized Phase 3 trials, and cross-study comparisons to historical controls carry inherent selection-bias limitations.

Trial	Cancer Type	Repurposed Agents	Reported Outcome vs. Historical Control
CUSP9	Glioblastoma	9 repurposed drugs + standard of care	30% alive/disease-free at 4+ years vs. 5–10% historically
METRICS	Glioblastoma, Stage IV (n=95)	Metformin, atorvastatin, mebendazole, doxycycline	64% two-year survival, 27.1-month median survival vs. 26–28% / 14–15 months
CLOVA	Recurrent, chemo-resistant GBM (n=7)	Cimetidine, lithium, olanzapine, valproate	11.2-month median survival after recurrence vs. 4.3–4.9 months (p=0.004)
COMBAT	Pediatric advanced solid tumors (n=74)	Celecoxib, vitamin D, fenofibrate, retinoic acid + chemo	High-grade sarcoma subgroup: 15.4-month median survival vs. 3.9 months (p=0.001)

The ReDO (Repurposing Drugs in Oncology) Project, a partnership between The Anticancer Fund and Global Cures, has catalogued 970 repurposed-drug trials across 45 countries. Because these compounds are off-patent, there is limited commercial incentive to fund the large trials that would be needed to move this evidence from "promising" to "standard of care" — which is a genuine structural barrier, not evidence of efficacy in itself.

9. Cancer Stem Cells: The Target Standard Therapy Misses

Cancer stem cells (CSCs) — typically 0.01% to 2% of a tumor — are a resilient subpopulation that drives relapse and metastasis. Unlike the rapidly dividing cells that chemotherapy and radiation are designed to kill, CSCs exhibit self-renewal and anti-apoptotic properties that make them comparatively resistant to conventional treatment. There is published evidence that chemotherapy and radiation can, in some contexts, promote CSC proliferation — meaning treatments that shrink the visible tumor may simultaneously spare or stimulate the cells most likely to cause recurrence. Currently, there are no FDA-approved therapies specifically targeting CSCs.

In vitro research has identified a number of affordable, already-available agents with anti-CSC activity, including metformin, ivermectin, mebendazole, doxycycline, curcumin, green tea extract (EGCG), berberine, melatonin, statins, and vitamin D3. This remains preclinical/mechanistic evidence in most cases; clinical translation and dosing for CSC-targeting specifically should be guided by a physician familiar with the relevant literature and the patient's individual case.

10. A Balanced Look: What the Skeptics and Reviews Say

No fair treatment of this topic should omit the substantial pushback in the literature and among prominent voices who have themselves moved through this space.

Systematic reviews are more cautious than individual case reports. A 2021 review of 39 studies concluded that "clinical evidence for the effectiveness of ketogenic diets in cancer patients is still lacking." A larger 2024 review of 252 randomized controlled trials concluded there is "limited evidence to support dietary interventions as a therapeutic tool in cancer care." A 2024 commentary in the Journal of the National Cancer Institute pushed back on that conclusion, arguing the review didn't adequately account for patient engagement/adherence or assess risk of bias — but the underlying point stands: the trial evidence is genuinely thinner than the case-report literature might suggest.

The ketogenic diet itself is not risk-free. A 2024 review in Current Problems in Cardiology argued the ketogenic diet "does not fulfill the criteria of a healthy diet" long-term, citing a comparison study in which a keto diet produced no BMI advantage over a balanced diet while causing significantly greater lean muscle mass loss. A 2026 Journal of Nutrition study in mice found ketogenic and high-fat diets caused elevated blood sugar and measurable liver damage compared to a high-carbohydrate group at matched calorie intake, and a 2025 Cell paper found high-fat feeding alters mitochondrial and oxidative stress pathways in ways that differ by sex. A 2023 Journal of Nutrition study led by Dr. Takashi Tamura (Nagoya University) found that men with low carbohydrate intake and women with high carbohydrate intake both faced increased mortality risk — an argument for a balanced diet rather than extreme restriction in either direction.

Even long-time low-carb advocates have revised their views. Dr. Joseph Mercola, author of the bestselling book Fat for Fuel and a long-time ketogenic/intermittent-fasting proponent, has publicly stated he now believes low-carb approaches carry serious metabolic downsides — citing his own experience and Dr. Ray Peat's bioenergetic model — and has shifted toward higher carbohydrate intake (primarily from whole fruit and rice) while continuing to view mitochondrial dysfunction as central to disease, including cancer. He explicitly still agrees with Seyfried's mitochondrial framing while disagreeing that a ketogenic diet is the correct clinical answer to it.

What this means practically: the mitochondrial/metabolic dimension of cancer biology is increasingly well-supported mechanistically (Warburg effect, PET scan biology, nuclear transfer experiments), but the specific clinical prescription — how strict a ketogenic diet should be, for how long, and for whom — remains genuinely contested even among people who agree on the underlying theory. Patient-level responses documented in observational case series are heterogeneous: alongside dramatic responders, there are patients with modest tumor shrinkage, stable disease, or no meaningful response. This is an evolving field, not a settled protocol.

11. Integrative Oncologists Using Metabolic Protocols

Board-certified oncologists explicitly implementing Seyfried's full press-pulse protocol remain rare, since it is still considered experimental. The following U.S. practitioners incorporate related ketogenic/metabolic strategies and often cite Seyfried's work directly:

Practitioner / Clinic	Credentials & Focus	Location
Dr. Dawn Lemanne — Oregon Integrative Oncology	Board-certified medical oncologist (Stanford-trained); personalized ketogenic diets, glucose-ketone index monitoring during radiation/chemo	Ashland, OR
Root Causes MD (Drs. Winters, Anderson, McKinney)	"Terrain 10" metabolic framework; explicitly references Seyfried's glucose-fermentation model; combines keto/low-carb with hyperthermia, IV nutrients, mistletoe	Fort Myers, FL
Dr. Ian D. Bier — Human Nature Natural Health	Naturopathic oncologist; ketogenic diet combined with hyperbaric oxygen therapy for metastatic cancers	Portsmouth, NH
Dr. Mel Schottenstein — Mitogenesis	Naturopathic doctor; personalized metabolic/mitochondrial-targeting plans citing Seyfried directly	Scottsdale, AZ
Leading Edge Clinic (Dr. Pierre Kory, Scott Marsland)	Adjunctive cancer care alongside standard oncology; repurposed drug combinations, metabolic intervention, CSC-targeting; telehealth in all 50 states; site for an IRB-approved observational study via Rebuild Medicine	Telehealth (US-wide)

Also see: Find an Integrative Oncologist directory, and consult a provider through The Wellness Company.

Glucose Ketone Index (GKI): a biomarker calculated as the ratio of blood glucose to blood ketones, used to gauge depth of therapeutic ketosis. A lower GKI indicates deeper ketosis; targets used in cancer metabolic therapy are typically far lower than those used for general weight management, and should be set and monitored by a treating clinician.

12. A Practical Prevention & Support Framework

Cancer prevention is not a single intervention — it is a layered, individualized approach. The following reflects a synthesis of the metabolic literature reviewed above and general cancer-prevention guidance. It is not a treatment protocol and should be adapted with a physician.

General Metabolic Health & Prevention Steps
Nourish	Plant-rich, whole-food diet (Mediterranean-style pattern); minimize ultra-processed foods, added sugar, refined grains, excess processed/red meat, alcohol, and smoking.
Evidence-based supplements	Vitamin D3: ~2,000 IU/day, adjusted to blood level, ideally with K2 and magnesium. Omega-3 (fish/krill oil): ~1 g/day. Bioavailable curcumin: ~500 mg/day. Green tea catechins (EGCG): ~500 mg/day, taken with food. Enhanced-absorption berberine: ~500 mg/day if overweight. Always confirm dosing and interactions with your physician, particularly if undergoing active cancer treatment.
Move	Combination of moderate aerobic exercise and resistance training, ~30 minutes/day.
Sleep & stress	Prioritize sleep quality and active stress management — Seyfried specifically flags chronic stress/elevated cortisol as a driver of blood sugar elevation that can feed fermentation-dependent cells.
Environment	Minimize known carcinogen and endocrine-disruptor exposure where practical.

A 2026 conceptual review outlines a broader seven-layer metabolic intervention framework for active disease management, integrating: (1) dietary metabolic modulation, (2) repurposed pharmacological agents (e.g., ivermectin, mebendazole), (3) mitochondrial-targeting agents (e.g., metformin), (4) anti-inflammatory nutraceuticals, (5) cancer stem cell targeting, (6) immune-metabolic support, and (7) lifestyle interventions. This is a research framework, not an established standard of care — for a broader resource organized by cancer type, see this cancer resource hub.

13. Frequently Asked Questions

Is the Metabolic Theory of Cancer accepted by mainstream oncology?
No — it remains a minority position. Standard oncology continues to operate primarily under the Somatic Mutation Theory framework, even though the Cancer Genome Atlas findings have raised significant questions about it. Most researchers in this space, including Seyfried, describe the two theories as needing reconciliation rather than treating MTOC as a wholesale replacement.

Does a ketogenic diet cure cancer?
No. There is no diet that "cures" cancer. Some preclinical and case-report evidence suggests ketogenic and calorie-restricted diets may complement standard treatment for certain cancer types, but systematic reviews of the randomized trial evidence describe the data as limited, and the diet carries its own risks (muscle loss, potential liver strain in some contexts) if not properly managed.

Should I stop chemotherapy or radiation to try a metabolic protocol instead?
The clinicians and researchers cited throughout this article, including Dr. Kory and Dr. Marik, explicitly do not recommend forgoing standard-of-care oncology. Metabolic and repurposed-drug approaches are presented in the literature as adjunctive, not as replacements.

What is the "press-pulse" protocol?
A framework developed by Thomas Seyfried combining a sustained metabolic "press" (ketogenic diet, glutaminase-targeting strategy, stress management) with an intermittent "pulse" (a targeted intervention, which may be non-toxic like hyperbaric oxygen/IV vitamin C, or conventional like chemotherapy/radiation) aimed at cells weakened by the press phase.

Are repurposed drugs like ivermectin or mebendazole approved for cancer treatment?
No. These are FDA-approved for other indications (e.g., parasitic infections) and are used off-label in the trials and clinics referenced here. Off-label use for cancer should only be undertaken under physician supervision with appropriate monitoring.

14. References

1. Seyfried TN. Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer. Wiley; 2012.
2. Christofferson T. Tripping Over the Truth. Chelsea Green; 2017.
3. Marik PE. Cancer Care: The Role of Repurposed Drugs and Metabolic Interventions. 2nd ed. 2024.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
5. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-314.
6. CUSP9 trial — PMC8349180; METRICS trial — PMC6610246; CLOVA trial — PMC5410264; COMBAT trial — Karger Oncology.
7. ReDO Project: redo-project.org
8. Kory P. "The Scientific Basis For The Somatic Mutation Theory Is Invalid." Substack, Aug 2024.
9. Kory P. "The Evolution And Validation Of The Metabolic Theory Of Cancer." Substack, Nov 2024.
10. Morgan G et al. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol. 2004.
11. BMC Cancer (2025). 30-day mortality after systemic anti-cancer therapy.
12. Seyfried TN et al. Mitochondrial-stem cell connection. PMC11051897. 2024.
13. Prolonged water-only fasting in follicular lymphoma: a case series. 2024. PMID 38956708.
14. Ketogenic diet reviews: PMID 33813635 (2021, 39 studies); PMID 38429997 (2024, 252 RCTs); JNCI commentary, 2024.
15. Current Problems in Cardiology (2024) — ketogenic diet review.
16. Journal of Nutrition (2026) — ketogenic diet mouse liver study; (2023) — Tamura et al., carbohydrate intake and mortality.
17. Cell (2025) — high-fat feeding and mitochondrial/oxidative stress pathways.
18. Clinical Nutrition (2021) — RCT, ketogenic diet in metastatic breast cancer.
19. Original source articles merged for this guide: Kory P, "Why Everything You've Been Told About Cancer May Be Wrong — And What the Science Actually Shows," Leading Edge Clinic, April 2026; OneDayMD Editorial Team, "Thomas Seyfried Cancer Treatment Protocol," onedaymd.com, updated 2026.

This article is for educational purposes only and does not constitute medical advice. Cancer is a serious, individualized disease, and treatment decisions should always be made in consultation with a qualified oncologist and/or integrative medicine physician. Metabolic and repurposed-drug approaches discussed here are adjunctive research strategies, not replacements for standard oncology care. Some links in this article are affiliate links, which may earn OneDayMD a commission at no additional cost to you.